Literature DB >> 17309646

Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population.

M Saeed1, M Perwaiz Iqbal, F A Yousuf, S Perveen, M Shafiq, J Sajid, P M Frossard.   

Abstract

Polymorphisms of paraoxonase gene (PON) cluster have been investigated in numerous studies for their association with myocardial infarction (MI) but the results have been conflicting. Epistasis and gene-environment interactions at this locus could possibly modulate susceptibility toward MI and account for the discrepancies. We carried out a case-control study (211 MI patients and 370 control subjects) to test association of PON cluster polymorphisms with MI, their interactions with each other and with smoking. Genotyping was performed by PCR-restriction fragment length polymorphism based assays. The Q192R, C-108T, and A148G polymorphisms were associated with MI. Two haplotypes consisting of C-108T, C311S, and A148G, having allele frequencies of 0.17 and 0.14 in the control population, predisposed to MI (global haplotype statistic chi2 = 34.74, df = 15, p = 0.0027). Multifactor dimensionality reduction analysis showed a significant three-locus model (p = 0.02) involving these three polymorphisms, suggesting a potential gene-gene interaction between PON1 and PON2. These polymorphisms also interacted with smoking, in a three-locus and a four-locus model (p = 0.01 and p = 0.05, respectively). Additionally, the R192 allele may advance the age-at-onset of MI. The PON cluster appears to be a susceptibility locus for MI in Pakistani population, and the susceptibility is modulated through gene-gene and gene-environment interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309646     DOI: 10.1111/j.1399-0004.2007.00753.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.

Authors:  Porat M Erlich; Kathryn L Lunetta; L Adrienne Cupples; Carmela R Abraham; Robert C Green; Clinton T Baldwin; Lindsay A Farrer
Journal:  Neurobiol Aging       Date:  2010-10-27       Impact factor: 4.673

2.  GREBP, a cGMP-response element-binding protein repressing the transcription of natriuretic peptide receptor 1 (NPR1/GCA).

Authors:  Guy Martel; Pavel Hamet; Johanne Tremblay
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

3.  Tetra primer ARMS-PCR relates folate/homocysteine pathway genes and ACE gene polymorphism with coronary artery disease.

Authors:  Rizwan Masud; Irfan Zia Qureshi
Journal:  Mol Cell Biochem       Date:  2011-05-13       Impact factor: 3.396

4.  An improved polymerase chain reaction-restriction fragment length polymorphism assay for the detection of a PON2 gene polymorphism.

Authors:  Xiaoran Duan; Yongli Yang; Tuanwei Wang; Xiaolei Feng; W U Yao; Zhen Yan; Wei Wang
Journal:  Biomed Rep       Date:  2016-05-13

Review 5.  Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: a systematic review.

Authors:  David Abelló; Elena Sancho; Jordi Camps; Jorge Joven
Journal:  Int J Mol Sci       Date:  2014-11-14       Impact factor: 5.923

Review 6.  Effects of paraoxonase 1 gene polymorphisms on heart diseases: Systematic review and meta-analysis of 64 case-control studies.

Authors:  Yazmín Hernández-Díaz; Carlos Alfonso Tovilla-Zárate; Isela Esther Juárez-Rojop; Thelma Beatriz González-Castro; Candelario Rodríguez-Pérez; María Lilia López-Narváez; José Manuel Rodríguez-Pérez; José Francisco Cámara-Álvarez
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 7.  Human paraoxonase 2.

Authors:  Sureerut Porntadavity; Thinnakorn Permpongpaiboon; Wanida Sukketsiri
Journal:  EXCLI J       Date:  2010-11-26       Impact factor: 4.068

8.  Paraoxonase gene polymorphism in south-western Korean population.

Authors:  Byoung-Soo Shin
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.